A recent study found that MDMA-assisted therapy could help veterans suffering from PTSD. Another paper from Johns Hopkins presented evidence that therapy in conjunction with psilocybin mushrooms can help ease the mental suffering of terminal cancer patients.
These findings, among others, were presented at the 2017 Psychedelic Science Conference in Oakland, California, where researchers gather every few years to discuss the potential medical applications of psychedelics, including LSD, psilocybin mushrooms, and MDMA. The field has exploded thanks to reforms at the Food and Drug Administration that allow researchers, for the first time in decades, to study the effects of these drugs.
The organizer of the conference was the Multidisciplinary Association for Psychedelic Studies (MAPS), which is also funding much of this breakthrough research.
"It's a fundamental right to explore one's own consciousness," says MAPS founder Rick Doblin. "We have the freedom of the press, the freedom of assembly, and the freedom of religion, and all those are based on the freedom of thought."
At this year's conference, Reason talked to researchers about the past, present, and future of this controversial and promising area of medical research.